Sansure Biotech(SH:688289) Zheng Quan Ri Bao Wang·2025-10-30 13:13Core Viewpoint - The company, Sansure Biotech, reported a revenue of 1.244 billion yuan for the first three quarters of 2025, marking a year-on-year growth of 20.49%, with a net profit attributable to shareholders of 191 million yuan and a non-recurring net profit of 157 million yuan [1] Group 1: Financial Performance - Revenue for the first three quarters reached 1.244 billion yuan, reflecting a 20.49% increase year-on-year [1] - Net profit attributable to shareholders was 191 million yuan, while non-recurring net profit stood at 157 million yuan [1] Group 2: Strategic Initiatives - The company is advancing its "integrated diagnosis and treatment" strategy through both external acquisitions and internal innovations, enhancing the synergy of its product matrix and technology platform [1] - Sansure Biotech plans to invest 370 million yuan to establish the Hunan Jin Furong Sansure Biotech Fund Partnership, aimed at expanding its business and extending its industrial chain [1][4] Group 3: Research and Development - The company invested 237 million yuan in R&D during the first three quarters, accounting for 19.07% of its revenue [2] - Over 130 new domestic and international registration certificates were obtained, including 9 Class III medical device registration certificates, totaling over 1,800 certifications [2] Group 4: Product Development - In the respiratory field, multiple small joint detection products were approved, enhancing the "6/3+X respiratory infection nucleic acid rapid detection scheme" [2] - The company has installed over 200 integrated machines this year, with significant growth in HPV product shipments, leading the industry [3] Group 5: Investment Fund - The planned fund aims to raise 1 billion yuan, with Sansure Biotech contributing 370 million yuan, representing a 37% stake [4] - Other limited partners include government-backed funds, indicating strong recognition of the company's industry position and past achievements [6]